MTOR and Hodgkins lymphoma: Aberrant activation of the PI3K/Akt/mTOR pathway is a hallmark of lymphomas, including Hodgkin lymphoma (HL) (59, 60) and non-Hodgkin lymphomas (NHLs) (61, 62).